trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Bempedoic acid does not increase the risk of muscle-related side effects.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
6 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Bempedoic acid does not increase the risk of muscle-related side effects?

Yes. Clinical trials and systematic reviews consistently demonstrate that bempedoic acid does not increase the risk of muscle-related side effects, making it a safe alternative for statin-intolerant patients.

Verdict: SUPPORTED · 6 sources for, 0 against · Last checked

The analysis

Multiple clinical trials, systematic reviews, and expert consensus papers (such as the CLEAR Outcomes trial data and subsequent analyses) establish that bempedoic acid operates via a liver-specific pathway (requiring ACSVL1 activation, which skeletal muscle lacks) and does not increase the incidence of myalgia or muscle-related side effects compared to placebo. There is unanimous support across the provided literature with no papers contradicting this finding.

Evidence for · 6
Reshaping Dyslipidaemia Treatment with Bempedoic Acid-A Narrative Review.
2025
The review highlights that bempedoic acid provides a liver-specific mechanism that lowers LDL-C while minimising muscle-related side effects.
Get citation
D, S., Z, B., I, R., F, Z., J, M., I, Z., M, T., AM, S., I, P., Z, R., & I, M. (2025). Reshaping Dyslipidaemia Treatment with Bempedoic Acid-A Narrative Review.. doi.org. https://doi.org/10.3390/biomedicines13061460

See more details
More for · 5
Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta analysis.
2024
The systematic review notes that the incidence of myalgia was not significantly increased and was actually reduced in the bempedoic acid group compared to statin-intolerant controls.
Get citation
M, H., W, S., CH, A., F, S., I, I., MD, T., M, A., S, H., S, N., & M, H. (2024). Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta analysis.. doi.org. https://doi.org/10.1080/14796678.2024.2388478

Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial.
2026
Analysis of the CLEAR Outcomes trial demonstrates that bempedoic acid discontinuation because of myalgia was comparable to placebo in both females and males.
Get citation
S, N., D, B., N, L., AM, L., SJ, N., SE, N., J, P., HA, P., P, R., & L, C. (2026). Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial.. doi.org. https://doi.org/10.1002/clc.70288

The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists.
2026
Expert opinion confirms that bempedoic acid achieves significant LDL-C reduction without relevant muscle-related adverse effects.
Get citation
M, F., R, B., R, C., S, D. C., A, P., G, R., G, S., & A, A. (2026). The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists.. doi.org. https://doi.org/10.1186/s12933-026-03185-1

Anti-HMGCR-Antibody-Positive Statin-Induced Myositis: A Pilot Case Series on Treatment with Bempedoic Acid and Immunosuppressive Therapy.
2025
Clinical case series demonstrate that bempedoic acid is a safe lipid-lowering alternative with minimal muscle toxicity in statin-intolerant patients.
Get citation
M, B., R, T., F, L. G., EAM, C., T, P., E, R., B, L., M, M., & M, I. (2025). Anti-HMGCR-Antibody-Positive Statin-Induced Myositis: A Pilot Case Series on Treatment with Bempedoic Acid and Immunosuppressive Therapy.. doi.org. https://doi.org/10.3390/antib14030063

Emerging Pharmacological Therapies in the Management of Hyperlipidemia.
2026
The review states that bempedoic acid offers an alternative mechanism via ATP citrate lyase inhibition, accomplishing prominent lipid reduction without muscle-related adverse events.
Get citation
N, S. & S, R. (2026). Emerging Pharmacological Therapies in the Management of Hyperlipidemia.. doi.org. https://doi.org/10.2174/0127724328440604260225063619

What does the evidence say?

Multiple clinical trials, systematic reviews, and expert consensus papers (such as the CLEAR Outcomes trial data and subsequent analyses) establish that bempedoic acid operates via a liver-specific pathway (requiring ACSVL1 activation, which skeletal muscle lacks) and does not increase the incidence of myalgia or muscle-related side effects compared to placebo. There is unanimous support across the provided literature with no papers contradicting this finding.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work